IGF2 and colorectal carcinoma: The available data also suggests that evaluation of circulating IGF2, together with the epigenetic alterations (e.g., IGF2 LOI), might be useful to assess the severity of the CRC and could be a target for a novel form of therapeutic strategy in CRC.